Company intelligence / Profile preview

Juno Therapeutics

Seattle, Washington, United Statesjunopharm.ca ↗

Ownership: Private
Development stage: Commercial

Overview

Juno's CAR T-cell product, Breyanzi (lisocabtagene maraleucel), was approved by the FDA in February 2021 for the treatment of adults with relapsed or refractory large-B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment[10]. Earlier clinical trials showed promising results with tumor shrinkage in patients with refractory leukemia and lymphoma[8].

Therapeutic areas: Oncology
Modalities: CAR T-cell therapyT cell receptor (TCR) technologies
Industry: Biotech

Drug pipeline

3 assets

lisocabtagene maraleucel

Commercial

Indications: Large B-cell lymphoma

2 more assets in the full pipeline.

Request access →

Partnerships

CelgeneJW Therapeutics (Chinese company co-founded by Juno)Fate TherapeuticsEditasAstraZeneca/MedImmune

Beyond the preview

Go deeper on Juno Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Juno Therapeutics.

Explore the full profile